Running Title: Nanopore polar body aneuploidy screening

Article Title: Evaluation of nanopore sequencing on polar bodies for routine pre-implantation genetic testing for aneuploidy.

Authors:

Anna Oberle, PhD[1], Franziska Hanzer, BSc[1], Felix Kokocinski, PhD[2], Anna Ennemoser, MSc[1], Luca Carli, PhD[1], Enrico Vaccari, PhD[1], Markus Hengstschläger, PhD[1], Michael Feichtinger, MD, PhD, MBA[1*]

Affiliation:

1 Wunschbaby Institut Feichtinger, Lainzer Straße 6, 1130 Vienna, Austria

2 Gene-Test Bioinformatics Solutions, Jakob-Müller-Str. 16, 68623 Lampertheim, Germany

***Corresponding author:** Michael Feichtinger, MD, PhD, EFRM-ESHRE/EBCOG, michael.feichtinger@wunschbaby.at, +43 1 8777775, Lainzerstrasse 6, 1130 Vienna, Austria

Article type: Other observational study: Study of screening and diagnostic tests

Funding Statement: The study was funded by the Wunschbaby Institut Feichtinger, Dr. Wilfried Feichtinger GmbH. No external funding was applied for this study.

Disclosure Statement: The authors declare no conflict of interest.

Attestation Statement:

- The subjects in this trial have not concomitantly been involved in other randomized trials (If applicable).
- Data regarding any of the subjects in the study has not been previously published unless specified.
- Data will be made available to the editors of the journal for review or query upon request.

Data Sharing Statement: The data files (raw and adjusted read counts per genomic region) can be freely accessed by other researchers for further analysis at https://www.gene-test.com/oberle-et-al-2023

Word Count: 294 words for abstract and 3412 words for text

Trial registration: not applicable

Capsule: Nanopore sequencing for aneuploidy analysis of polar bodies is feasible for clinical routine analysis, inexpensive and shows high concordance rates with standard detection methods.

Structured Abstract:

Objective: To evaluate third-generation nanopore sequencing for aneuploidy screening on pooled polar bodies for the applicability in clinical routine.

Design: Comparative experimental study of polar body array comparative genome hybridization (aCGH) aneuploidy results compared with nanopore sequencing.

Subjects: A total of 102 pooled polar body samples from 20 patients undergoing fertility treatment.

Intervention: None.

Main Outcome Measures: Concordance of nanopore sequencing aneuploidy results with reference results generated by aCGH and detailed analysis of time and cost for nanopore sequencing workflow.

Results: Aneuploidy screening results between nanopore sequencing and aCGH of 99 pooled polar body samples were compared, three samples were excluded because of failed or uninterpretable results. Overall, 96 samples were consistently detected as euploid or aneuploid in both methods (concordance=97.0%, sensitivity = 0.957, specificity = 1.0, PPV = 1.0, NPV = 0.906) and 91 samples showed a fully concordant karyotype (92%). On a chromosomal level, concordance reached 98.7%. Chromosomal aneuploidies analyzed in this trial covered all 23 chromosomes with 98 trisomies, and 97 monosomies in 70 aCGH samples.

Detailed calculation of time and cost for the nanopore sequencing workflow was performed for different scenarios. Time calculation revealed that the whole nanopore workflow is feasible in under 5 hours (for one sample) with maximum time of 16 hours (for 12 samples in parallel). This enables fresh PB euploid embryo transfer. Material cost for the whole workflow range between 100€ and 150€, including sequencing cost of 40€ per sample, resulting in cost-efficient aneuploidy screening.

Conclusion: This is the first clinical study, systematically comparing nanopore sequencing for aneuploidy of pooled polar bodies with standard detection methods. High concordance rates

confirmed feasibility of nanopore technology for this application. Additionally, the fast and cost-efficient sequencing workflow reveals clinical utility of this technology, making polar body PGT-A clinically attractive.

Keywords

PGT-A, Polar Body Biopsy, Nanopore Sequencing, Oxford Nanopore Technology, Cost effective PGT-A

Introduction

With increasing female age, the probability for aneuploid embryos increases and with it the risk of age-related infertility, abortions and children born with aneuploidies (1). Early pregnancy loss and spontaneous abortions are most frequently caused by chromosomal abnormalities of the embryo (2). In contrast to maternal age, paternal age plays a minor role for chromosomal abnormalities (3). Preimplantation-genetic testing for aneuploidy (PGT-A) is used to screen for unbalanced chromosomal distributions before implantation and can therefore reduce miscarriage rates and improve pregnancy and life-birth rates per embryo-transfer, especially in patients with advanced-maternal age (4,5).

DNA analyzed in PGT-A can originate from trophectoderm cells, blastomere cells or polar bodies (PB). All three sources have advantages and specific limitations. While polar body analysis allows the detection of meiotic maternal aneuploidies only, the analysis of trophectoderm biopsy (TEB) and blastomere biopsy can detect embryogenic aneuploidies. However, blastomere biopsy can possibly damage the embryo (6,7) and was shown to provide limited clinical benefit (8) and is therefore not commonly performed anymore. In TEB analysis, which is currently seen as the gold standard for PGT-A, diagnosed trophectoderm aneuploidies might differ from embryogenic material of the inner cell mass due to mosaicisms (9). Embryos classified as aneuploid or mosaic by TEB can lead to euploid, healthy life-births, indicating discordances between inner cell mass and trophectoderm or self-repair mechanisms (10,11).

In contrast, PGT-A using PB biopsy leaves less room for interpretation, since mitotic errors in cell division leading to mosaicisms are not detected here. In a large multicenter randomized clinical trial ('ESHRE Study into the Evaluation of oocyte Euploidy by Microarray analysis', ESTEEM trial), PGT-A using PB was shown to significantly reduce the number of embryo transfer needed for live birth, reduce number of cryopreserved embryos and reduce miscarriage rates (12). These findings highlight the clinical benefit for PGT-A using PB. In contrast to PGT-A using TEB, PB biopsy allows fresh embryo transfer and can avoid freeze-all procedures. Additionally, due to legal restrictions for TEB analysis in

26 several European countries, PB biopsy is often the only option and is performed frequently in countries
27 like Germany or Austria (13,14).
28 However, PB analysis was previously stated to be not cost effective (15,16). Lowering the cost for PB-
29 based PGT-A and PGT-A in general is therefore an important goal to improve patient acceptance and
30 accessibility.
31 PGT-A is often performed using short-read next-generation sequencing (NGS), which requires high
32 initial investment costs and high running expenses. Third-generation sequencing using nanopores is a
33 novel technology with the potential to perform sequencing in a fast, easy, and cost-effective way,
34 enabling application even in small and less well-financed clinics (17). Continuous development of the
35 technology led to significant improvements in sequencing quality (18,19).
36 Feasibility of nanopore sequencing for PGT was mainly shown for structural variants and monogenetic
37 disease (20–24), which comes with high costs and is far from clinical routine (22). PGT-A from TEB
38 samples using nanopore sequencing was first demonstrated in a small pilot study (25). A follow-up
39 study compared their optimized nanopore aneuploidy analysis of 52 chorionic villi samples, 50
40 amniotic fluid samples, 64 placental or fetal tissue samples and 52 TEB samples with standard NGS
41 PGT-A screening (26). Overall, the authors saw very good concordance rates. The optimized nanopore
42 workflow was notably faster (2-6 hours) and more cost-effective (around 50 US$ sequencing cost per
43 sample) compared to traditional NGS screening (26). This was the first systematic clinical evaluation of
44 nanopore sequencing for aneuploidy including PGT-A with TEB samples. However, due to limited
45 sample number and missing independent external verification of PGT-A samples in this study, further
46 clinical studies are needed to transfer the technology into clinical PGT-A routine analysis.
47 In the present study, pooled PBs from 102 oocytes were analyzed using nanopore sequencing and
48 compared to results generated as part of the clinical routine using array comparative genomic
49 hybridization (aCGH). This is the first study that analyses aneuploidy from PB samples using nanopore
50 sequencing technology including detailed cost analysis of the nanopore sequencing workflow.

51 **Material and Methods**

52 *Study design and sampling:*

In this comparative study, 102 pooled PB samples from 20 patients treated for infertility between March and December 2022 were prospectively collected and analyzed for aneuploidy using nanopore sequencing technology. Nanopore sequencing results were compared with aCGH results generated as part of the clinical routine. All patients participating in this trial were treated for infertility at 'Wunschbaby Institut Feichtinger' (WIF) in Vienna and chose aneuploidy screening of their polar bodies. All patients provided written informed consent. The study was approved by the Ethic Committee of the Medical University Vienna (EK-1249/2022). After oocyte pick-up and fertilization by intracytoplasmic sperm injection (ICSI), both PBs were taken simultaneously 16 to 18 hours after fertilization and placed in a sterile PCR tube with 2.5 µl of fresh, sterile phosphate-buffered saline (PBS). Opening of the zona pellucida was performed using RI Saturn 5 Active™ (Research Instruments Ltd, UK). PB samples were frozen at -20°C and transported to an external genetic diagnostic laboratory for routine analysis.

53 *DNA Amplification and reference analysis:*

54 PGT-A routine analysis of pooled PBs was performed after the standard GentiSure Pre-Screen Kit for
55 Single Cell Analysis Kit (Agilent Technologies, USA) protocol, including Whole Genome Amplification
56 (WGA) with REPLI-g Single Cell Kit using a phi29 polymerase process (QIAGEN, Germany), Fluorescent
57 Labeling and CGH Microarray. This standard protocol was adapted for PB diagnosis. Around 5µg of
58 WGA aliquots from PB samples were anonymized and used for nanopore sequencing.

59 *Nanopore Library Preparation:*

60 After receiving anonymized WGA DNA samples, quality was confirmed by agarose gel electrophoresis
61 (Thermo Fisher Scientific, USA) and quantity was measured by Qubit 4 fluorometer (Thermo Fisher
62 Scientific, Singapore). Then WGA DNA was purified using gDNA Clean & Concentrator-25 columns
63 (Zymo Research, USA).

64 As part of the protocol optimization, around 1.5 µg of purified DNA was prepared for some samples by
65 digestion of single-stranded regions using T7 Endonuclease I (New England Biolabs (NEB), UK) to
66 reduce or remove branched structures which were introduced during amplification. DNA was purified
67 using gDNA Clean & Concentrator-25 columns (Zymo Research, USA) and eluted in 50µl nuclease-free
68 water.
69 For library preparation, the Oxford Nanopore Technology (ONT, UK) Kits 'Ligation Sequencing Kit' (SQL-
70 LSK109) and 'Native Barcoding Expansion' (EXP-NBD104) were used according to manufacturer's
71 recommendations, as previously tested in a pre-clinical trial (27).
72 Briefly, 1 - 1.5 µg purified DNA was repaired and end-prepared using NEBNext® FFPE DNA Repair and
73 Ultra™ II End-prep Mix (both from NEB, UK) and purified using DNA Clean & Concentrator-5 columns
74 (Zymo Research). For native barcode ligation, 500 to 700 ng DNA was incubated using ONT Native
75 Barcodes and Blunt/TA Ligase Master Mix (NEB) and purified using DNA Clean & Concentrator-5
76 columns (Zymo Research). Purified, barcoded DNA samples for one sequencing run (between 4 to 8
77 samples, see Supplementary Table S1) were pooled equimolar in one tube and ligated to AMII adapters
78 (ONT) with NEBNext® Quick Ligation Reaction Buffer and Quick T4 DNA Ligase (both NEB). For the final
79 clean-up, 0.5x SPRIselect beads (Beckman Coulter, USA) were utilized to ensure elimination of small
80 DNA fragments and washed with Short Fragment Buffer (ONT) before elution.
81 *Nanopore sequencing:*
82 The sequencing-ready library was primed and loaded on a MinION R9.4 flow cell (FLO-MIN106D, ONT)
83 according to manufactures recommendation using 25-50 fmol DNA library. Sequencing was performed
84 on MinION Mk1C with simultaneous base calling using standard base calling settings and quality
85 threshold (minimum Q-score) of 8. Sequencing time was adapted according to number of samples
86 pooled and quality of the flow cell (pores available) with average sequencing time of around 9 hours
87 for 6 pooled PB samples resulting in a median number of 105,670 reads (after pre-processing, stdev=
88 76,444) and 210 Mbases (stdev=100) generated per sample (detail sequencing constitution, time and
89 output in Supplementary Table S1).

90 *Data analysis:*

91 Nanopore's *MinKNOW* software system controls the raw data acquisition, performing basecalling and
92 demultiplexing with *Guppy* as well as FASTQ file creation. Following on, a data analysis pipeline was
93 applied, developed for long read-based PGT-A data using standard bioinformatics tools and custom
94 software scripts. The specific processing steps are described in the following.

95 Primary data analysis consisted of read cleaning with *Porechop* (Porechop, RRID:SCR_016967) and
96 *Nanofilt* (28), alignment to the human genome GRCh38 with *minimap2* (29) and creation of BAM files
97 with *samtools* (30). Secondary processing steps made use of the *QDNAseq* R software package (31)
98 and include binning of reads using a custom 500 kb bin matrix, GC content and mappability correction,
99 median and reference normalisation, smoothing, segmentation and copy-number calling. A set of five
100 samples were used as a combined reference to capture experiment-specific bias. They represented
101 the first few samples of the study with a representative profile and without whole-chromosome copy-
102 number changes as assessed by aCGH. Further processing was performed to filter and summarize the
103 data, producing a report with genome-wide copy-number plots, noise measurements and
104 automatically detected changes per chromosome and sample. Samples with more than 3 aneuploid
105 chromosomes were classified as 'multiple'.

106 As quality measures of the nanopore sequencing samples, MAPD (Median of the Absolute values of all
107 Pairwise Differences) and noise (median standard deviation of normalised read counts within each
108 segment) values are reported for all chromosomes as well as for each sample and automatically plotted
109 in the chromosomal distribution plots. Samples resulting in a total noise value greater than 0.6 and
110 MAPD value greater than 1.7 were excluded from the comparison (Supplementary Table S1).

111 **Results**

112 In this study, 102 pooled PB samples from 20 patients were analyzed for PGT-A by nanopore
113 sequencing and compared to clinical routine PGT-A analysis by aCGH. All samples were successfully
114 amplified while a negative control (culture medium) for each batch showed no amplification and aCGH
115 was performed for all 102 PB samples. WGA aliquots were anonymized and used for nanopore
116 sequencing. Schematic study design is shown in Figure 1.

117

118 *Quality control and genome coverage for nanopore sequencing workflow:*

119 In total three samples were excluded from the comparison. Two samples (PB61, PB95) were excluded
120 due to failed or uninterpretable aCGH (2 %) and one sample (PB48, 1%) was excluded due to failed
121 quality check after nanopore sequencing with noise and MAPD values below quality threshold.

122 Data analysis from nanopore sequencing results revealed medium sequencing output of 210 Mbases
123 and a median of 105,670 reads per sample (after pre-processing, 70 to 650 Mbases and 32,924 to
124 374,841 reads). A median of 3% (88 Mbases) of the genome was covered by one or more reads
125 (between 0.9 – 9.3%). With the 0.5 Mbases bin matrix applied in the analysis, a smoothing window of
126 6 bins and a calling limit of 20 bins, the application has a theoretical resolution of around 10 Mbases.
127 This is comparable with the common resolution for PGT-A using aCGH or NGS (6-10 Mbases) (32).
128 Average Q-score of all nanopore-sequenced samples was 8. Quality was additionally verified in the
129 bioinformatic data analysis pipeline by noise and MAPD values. Average noise of all samples was 0.428
130 (between 0.230 and 0.724) and average MAPD was 1.164 (between 0.720 and 1.809). All noise and
131 MAPD values are listed in Supplementary Table S1 and realtionship between both quality measures is
132 visualized in Supplementary Figure S1.

133

134 *Comparison of PGT-A results from nanopore sequencing with routine aCGH results:*

135 In total, 99 pooled PB samples for PGT-A screening were utilized in this study for comparison of aCGH
136 with nanopore sequencing workflow. From these, 29 were detected euploid (29.3 %) and 70 were

137 detected aneuploid (70.7 %) by aCGH reference. This is expected, given the patient cohort with
138 medium female age of 40.5 years. Nanopore sequencing analysis detected 32 samples as euploid and
139 67 as aneuploid resulting in 97.0 % sample-level concordance and a sensitivity of 0.957, specificity of
140 1.0 with a positive predictive value (PPV) of 1.0 and a negative predictive value (NPV) of 0.906 (Figure
141 1). The results of all aCGH and nanopore sequencing analyses are listed in Table 1. Three samples
142 detected as aneuploid using aCGH revealed an euploid chromosomal pattern using nanopore
143 sequencing. All three samples showed a single aneuploid chromosome (+22, +19, -16, respectively) by
144 aCGH and these elevations or reductions were visible but below threshold at nanopore sequencing, as
145 listed in Supplementary Table S1.
146 In total, aCGH analysis detected 195 aneuploid chromosomes in the 99 samples, with 98 trisomies and
147 97 monosomies covering all 23 chromosomes, shown in Figure 3. Counting the exact match (all
148 chromosomes concordant but assigning “multiple” to karyotypes with more than three aberrations),
149 we found 91.9% (karyotype-level) concordance (91 of 99 samples showing exact match), as listed in
150 Table 1. On chromosomal level, we found 98,7% concordance (2244 of 2273 chromosomes were
151 concordantly identified as normal or abnormal). Sensitivity was 0.901, specificity 0.995, PPV 0.945 and
152 NPV 0.991 per chromosome. Segmental changes were not addressed in this study. Example
153 chromosomal distribution plots of euploid and aneuploid detected samples, which are automatically
154 created from bioinformatic data analysis pipeline after nanopore sequencing are shown in Figure 4.
155 To assist the physicians and patients in the process of decision-making, a further critical evaluation of
156 euploid-detected PBs can be performed and marginal/borderline elevated or reduced chromosomes
157 can be mentioned together with the euploid result in the clinical report. Here, we performed manual
158 revision of all euploid-detected samples after nanopore sequencing and the additional information
159 about slightly elevated or reduced chromosomes can be found in Supplementary Table S1.
160
161 *Endonuclease digestion step:*

162 As part of this study, we evaluated the importance of an endonuclease digestion step. 28 samples were
163 run in parallel with and without endonuclease digestion step. While samples with a high signal to noise
164 ratio show matching results, the additional digestion clearly reduces noise and improves calling for
165 challenging cases. Reduction of average noise and MAPD values, as well as improvements of
166 sequencing-output per time is shown in Figure 5. Detailed comparison of sequencing results with and
167 without endonuclease digest is listed in Supplementary Table S2. For the calculation of concordance
168 between aCGH and nanopore sequencing, results after Endonuclease digest were utilized for all these
169 samples. For all new investigations we recommend adding this step.
170
171 *Detailed time and cost calculation:*
172 To evaluate if nanopore sequencing for PGT-A can be utilized in clinical routine, we performed a
173 detailed time and cost analysis for our nanopore sequencing workflow, which is listed in
174 Supplementary Tables S3 and S4. The nanopore sequencing workflow used in this study starting from
175 amplified DNA until ploidy result is feasible in one and a half hours with one sample being sequenced
176 separately. For 12 samples being sequenced in parallel, the workflow is feasible in around 12 hours
177 (Supplementary Table S3). Amplification of the pooled PB additionally take between 1.5 hours and 4.5
178 hours per sample, depending on the WGA kit. In our study, WGA was performed using REPLIg Single
179 Cell Kit (QIAGEN) with a 2.5 h amplification protocol.
180 Material cost for the whole workflow, including WGA, sample preparation, sequencing and data
181 analysis range from 100€ to 220€ per sample. A detailed list of time and cost calculation for different
182 scenarios is shown in Supplementary Table S3 and S4. Initial investment cost for nanopore sequencing
183 can be neglected because prices for nanopore starter packages, where MinION sequencing machines
184 are included cover material costs.
185

186 **Discussion**

187 The present study is the first study that systematically compares PB PGT-A analysis using nanopore
188 sequencing with routine aCGH analysis. The concordance rate between both technologies found in this
189 study was 97% for euploid/aneuploid sample decision and 99% on chromosomal level. These
190 concordance rates are high, given the different nature of the methods and the delicate sample type of
191 PB biopsy. Similar studies comparing different technologies for PGT-A analysis received slightly higher
192 concordance rates (26,33–35). However, genetic material utilized in these studies was originated from
193 TEB, which comprises significantly more genetic starting material than PB biopsy, resulting in more
194 stable and uniform whole genome amplification. From 102 PB samples analyzed with nanopore
195 sequencing in our study, 101 samples passed the quality threshold, indicating a high reliability of the
196 technology.

197

198 Nanopore sequencing has several advantages, compared to aCGH or NGS analysis, including but not
199 limited to the fast turnaround time, inexpensive sequencing, as well as small initial investment costs
200 needed. These advantages might lead to cost-efficient diagnostics for clinical applications. Time and
201 cost of nanopore sequencing for clinical reproductive healthcare has been reported in several
202 publications, but detailed statements on how these number can be achieved are often not stated
203 (20,25,26,38). Here, we provide detailed insight in material costs and preparation, sequencing, and
204 data analysis time for different scenarios (Supplementary Table S3 and S4).

205 Another advantage of nanopore sequencing compared to aCGH or NGS is the high flexibility of the
206 sequencing method. Sequencing data as well as quality measures of the data generated, and the flow
207 cell health can be monitored in real-time during nanopore sequencing. If more data is required or
208 quality of the library is poor, sequencing can easily be prolonged or repeated on the same flow cell
209 until enough data is generated. This can reduce the necessity to repeat uninterpretable results and can
210 reduce prolonged time-to diagnosis, increasing the possibility for same-cycle transfer of euploid

211 embryos, leading again to a cost reduction by reducing freeze-all procedures and hormonal treatment
212 for the embryo transfer, possibly leading to a shorter time-to-pregnancy.
213
214 A possible limitation of the study derives from the reference method. In a comparable study using
215 nanopore sequencing in comparison with standard clinical detection methods (NGS, FISH, aCGH),
216 discordant aneuploidy results were re-examined and the initial nanopore sequencing results were
217 confirmed in these samples, showing that even established clinical testing methods like FISH or aCGH
218 might result in misdiagnosis (26). Misdiagnosis of routine aCGH PGT-A analysis has also been shown in
219 a study comparing aCGH with NGS results (34). In the present study using material from pooled PBs,
220 re-examination of aCGH was not possible due to limited sample resource.
221 For some samples in this study, the reference result remained unclear, due to increased noise and
222 limited resolution of the aCGH method. In particular, the small chromosomes show higher variability
223 in both platforms. Discordant results could originate from different thresholds defined in aCGH and
224 nanopore sequencing, different analysis bias and bias reduction (in the nanopore workflow, bias was
225 reduced through binning, GC content and mappability correction, median and reference
226 normalisation), or different genome covargae and resolution. Although the reference method has
227 been extensively validated (5) and is applied in clinical routine since 2015, the utilization of pooled PBs,
228 analyzed with aCGH might come with some technical limitations, including limited resolution and the
229 necessity for manual revision. While the assessment and quantification of the nanopore sequencing
230 results is clearer, manual review is still recommended and sometimes required. A larger study with
231 follow-up data or a clinical non-selection trial would be beneficial for increased confidence.
232 Independent of the technology, the analysis of chromosomal material is complicated by the different
233 characteristics of human chromosomes (36). The short chromosomes 19, 20, 21, 22 and Y provide
234 limited material which leads to an increased variability in measurements. The GC-richest chromosomes
235 16, 17, 19 and 22 often display increased levels of noise. Also, chromosomes with heterochromatic
236 polymorphisms, like chromosomes 1, 9 and 16 differ due to normal, benign variations in

237 heterochromatin-content, which can be visualized by microscopy but are hard to interpret in
238 sequencing-based methods or aCGH (37). In our study, the chromosomes 9, 19, 21 and 22 showed
239 most discordances (Figure 3).
240
241 Although manual review of the chromosomal distribution of each sample is recommended, our data
242 analysis pipeline automatically generates the sequencing plot with significantly abnormal
243 chromosomes being highlighted and quality measures (noise and MAPD) are plotted for each
244 chromosome. The karyotype is reported automatically according to the optimized bioinformatic
245 pipeline. This automation together with the clear and easy-to-read karyotype plot makes the nanopore
246 sequencing data very easy to understand and interpret. Interpretation of the results does not require
247 years of expert knowledge and experience, which is often required for the interpretation of aCGH
248 plots. The automated analysis pipeline is not dependent on subjective decision-making of the
249 responsible geneticist or physician.
250 Nevertheless, following the clinical practice, we additionally performed manual review of all euploid-
251 detected samples (Supplementary Table S1). This additional annotation about slight chromosomal
252 aberrations does not change the automatically reported result (euploid) but can be provided as
253 additional information in the medical report. This report can facilitate the embryo prioritization and
254 decision-making for the physician and the patients as part of their fertility treatment.
255
256 Taken together, pooled PB nanopore sequencing revealed high concordance rates compared to
257 conventional aCGH with minimized time and financial resources required.
258
259 **Acknowledgements**
260 We would like to thank all patients participating in this study. We also thank all staff members from
261 HLN Genetic GmbH for providing the reference samples.

References

262 1. Franasiak JM, Forman EJ, Hong KH, Werner MD, Upham KM, Treff NR, et al. The nature of
263 aneuploidy with increasing age of the female partner: a review of 15,169 consecutive
264 trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril
265 2014;101(3).
266 2. Petracchi F, Colaci DS, Igarzabal L, Gadow E. Cytogenetic analysis of first trimester pregnancy
267 loss. Int J Gynaecol Obstet 2009;104(3):243–4.
268 3. Fonseka KGL, Griffin DK. Is there a paternal age effect for aneuploidy? Cytogenet Genome Res
269 2011;133(2–4):280–91.
270 4. Rubio C, Bellver J, Rodrigo L, Castillón G, Guillén A, Vidal C, et al. In vitro fertilization with
271 preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized,
272 controlled study. Fertil Steril 2017;107(5):1122–9.
273 5. Feichtinger M, Stopp T, Göbl C, Feichtinger E, Vaccari E, Mädel U, et al. Increasing Live Birth
274 Rate by Preimplantation Genetic Screening of Pooled Polar Bodies Using Array Comparative
275 Genomic Hybridization. PLoS One 2015;10(5):e0128317.
276 6. Cohen J, Wells D, Munné S. Removal of 2 cells from cleavage stage embryos is likely to reduce
277 the efficacy of chromosomal tests that are used to enhance implantation rates. Fertil Steril
278 2007;87(3):496–503.
279 7. Scott RT, Upham KM, Forman EJ, Zhao T, Treff NR. Cleavage-stage biopsy significantly impairs
280 human embryonic implantation potential while blastocyst biopsy does not: a randomized and
281 paired clinical trial. Fertil Steril 2013;100(3):624–30.
282 8. Mastenbroek S, Twisk M, van Echten-Arends J, Sikkema-Raddatz B, Korevaar JC, Verhoeve HR,
283 et al. In Vitro Fertilization with Preimplantation Genetic Screening. N Engl J Med
284 2007;357(1):9–17.
285 9. Viotti M, Victor AR, Barnes FL, Zouves CG, Besser AG, Grifo JA, et al. Using outcome data from
286 one thousand mosaic embryo transfers to formulate an embryo ranking system for clinical

287 use. Fertil Steril 2021;115(5):1212–24.

288 10. Greco E, Minasi MG, Fiorentino F. Healthy Babies after Intrauterine Transfer of Mosaic
289 Aneuploid Blastocysts. N Engl J Med 2015;373(21):2089–90.

290 11. Treff NR, Marin D. The “mosaic” embryo: misconceptions and misinterpretations in
291 preimplantation genetic testing for aneuploidy. Fertil Steril 2021;116(5):1205–11.

292 12. Verpoest W, Staessen C, Bossuyt PM, Goossens V, Altarescu G, Bonduelle M, et al.
293 Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in
294 advanced maternal age: a randomized clinical trial. Hum Reprod 2018;33(9):1767–76.

295 13. Hengstschläger M, Feichtinger W. Die erste Präimplantationsdiagnostik in Österreich. Wien
296 Klin Wochenschr 2005;117(21–22):725–7.

297 14. Ven K van der, Montag M, Ven H van der. Polar Body Diagnosis – A Step in The Right
298 Direction? Dtsch Arztebl Int 2008;

299 15. Neumann K, Griesinger G. An Economic Analysis of Aneuploidy Screening of Oocytes in
300 Assisted Reproduction in Germany. Geburtshilfe Frauenheilkd 2020;80(2):172–8.

301 16. Neumann K, Sermon K, Bossuyt P, Goossens V, Geraedts J, Traeger-Synodinos J, et al. An
302 economic analysis of preimplantation genetic testing for aneuploidy by polar body biopsy in
303 advanced maternal age. BJOG An Int J Obstet Gynaecol 2020;127(6):710–8.

304 17. Cabibbe AM, Spitaleri A, Battaglia S, Colman RE, Suresh A, Uplekar S, et al. Application of
305 Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-
306 Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. J Clin Microbiol
307 2020;58(10).

308 18. Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME, Gouil Q. Opportunities and challenges in
309 long-read sequencing data analysis. Genome Biol 2020;21(1).

310 19. Jain M, Koren S, Miga KH, Quick J, Rand AC, Sasani TA, et al. Nanopore sequencing and
311 assembly of a human genome with ultra-long reads. Nat Biotechnol 2018 364 2018;36(4):338–
312 45.

313 20. Cretu Stancu M, van Roosmalen MJ, Renkens I, Nieboer MM, Middelkamp S, de Ligt J, et al.
314 Mapping and phasing of structural variation in patient genomes using nanopore sequencing.
315 Nat Commun 2017;8(1):1326.
316 21. Pei Z, Deng K, Lei C, Du D, Yu G, Sun X, et al. Identifying Balanced Chromosomal Translocations
317 in Human Embryos by Oxford Nanopore Sequencing and Breakpoints Region Analysis. Front
318 Genet 2022;0:2723.
319 22. Margolis C, Werner M, Jalas C. Variant haplophasing by long-read sequencing: proof of
320 concept in preimplantation genetic workup and an opportunity to distinguish balanced and
321 normal embryos. Fertil Steril 2021;116(3):668–9.
322 23. Hu L, Liang F, Cheng D, Zhang Z, Yu G, Zha J, et al. Location of Balanced Chromosome-
323 Translocation Breakpoints by Long-Read Sequencing on the Oxford Nanopore Platform. Front
324 Genet 2019;10(January):1313.
325 24. Madjunkova S, Sundaravadanam Y, Antes R, Abramov R, Chen S, Yin Y, et al. Detection of
326 Structural Rearrangements in Embryos. N Engl J Med 2020;382(25):2472–4.
327 25. Wei S, Weiss ZR, Gaur P, Forman E, Williams Z. Rapid preimplantation genetic screening using
328 a handheld, nanopore-based DNA sequencer. Fertil Steril 2018;110(5):910-916.e2.
329 26. Wei S, Djandji A, Lattin MT, Nahum O, Hoffman N, Cujar C, et al. Rapid Nanopore Sequencing-
330 Based Screen for Aneuploidy in Reproductive Care. N Engl J Med 2022;387(7):658–60.
331 27. Oberle A, Carli L, Ennemoser A, Hengstschläger M, Feichtinger M. P-533 Single-cell long-read
332 nanopore sequencing as a fast and cost-efficient method for aneuploidy detection and
333 potentially PGT-A, a pre-clinical study. Hum Reprod 2022;37(Supplement_1).
334 28. De Coster W, D'Hert S, Schultz DT, Cruts M, Van Broeckhoven C. NanoPack: visualizing and
335 processing long-read sequencing data. Bioinformatics 2018;34(15):2666–9.
336 29. Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics
337 2018;34(18):3094–100.
338 30. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence

339 Alignment/Map format and SAMtools. Bioinformatics 2009;25(16):2078–9.

340 31. Scheinin I, Sie D, Bengtsson H, van de Wiel MA, Olshen AB, van Thuijl HF, et al. DNA copy
341 number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing
342 with identification and exclusion of problematic regions in the genome assembly. Genome Res
343 2014;24(12):2022–32.

344 32. Snider AC, Darvin T, Spor L, Akinwole A, Cinnioglu C, Kayali R. Criteria to evaluate patterns of
345 segmental and complete aneuploidies in preimplantation genetic testing for aneuploidy
346 results suggestive of an inherited balanced translocation or inversion. F&S Reports
347 2021;2(1):72–9.

348 33. Kung A, Munné S, Bankowski B, Coates A, Wells D. Validation of next-generation sequencing
349 for comprehensive chromosome screening of embryos. Reprod Biomed Online
350 2015;31(6):760–9.

351 34. Sachdeva K, Discutido R, Albuz F, Almekosh R, Peramo B. Validation of Next-Generation
352 Sequencer for 24-Chromosome Aneuploidy Screening in Human Embryos. Genet Test Mol
353 Biomarkers 2017;21(11):674–80.

354 35. Walters-Sen L, Neitzel D, Bristow SL, Mitchell A, Alouf CA, Aradhya S, et al. Experience
355 analyzing >190,000 embryo trophectoderm biopsies using a novel FAST-SeqS PGT assay.
356 Reprod Biomed Online 2021;

357 36. Piovesan A, Pelleri MC, Antonaros F, Strippoli P, Caracausi M, Vitale L. On the length, weight
358 and GC content of the human genome. BMC Res Notes 2019;12(1):106.

359 37. Hernandez-Nieto C, Gayete-Lafuente S, Alkon-Meadows T, Lee J, Luna-Rojas M, Mukherjee T,
360 et al. Parental chromosomal heteromorphisms are not associated with an increased risk of
361 embryo aneuploidy. JBRA Assist Reprod 2021;25(4):575–80.

362 38. Bartalucci N, Romagnoli S, Contini E, Marseglia G, Magi A, Guglielmelli P, et al. Long Reads,
363 Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. Clin
364 Chem 2019;65(12):1604–5.

Figure and Table Legends:

Figure 1: Study design including concordance rates found in this study. WGA: whole-genome amplification; PGT-A: preimplantation-genetic testing for aneuploidy; aCGH: array comparative-genomic hybridization; PPV and NPV: positive and negative predictive value.

Figure 2: Schematic overview of the nanopore sequencing workflow, including time measures for individual procedures, embedded in the clinical PGT-A workflow. Prorate sequencing time per sample was calculated according to medium sequencing time for 6 pooled samples. Separate sequencing of one sample can be shorter. ICSI: intra-cytoplasmatic sperm injection; PB: polar body; WGA: whole-genome amplification.

Figure 3: Occurrence of whole-chromosome aneuploidies in all 99 pooled PB samples. TP: true positive, FN: false negative, FP: false positive.

Figure 4: Example chromosomal distribution plots from automatically generated nanopore sequencing workflow. Quality values noise and MAPD are mapped for each chromosome and thresholds for the total sample (0.6 and 1.7, respectively) are highlighted in red. MAPD: Median of the Absolute values of all Pairwise Differences; noise: median standard deviation of normalised read counts within each segment.

Figure 5: Comparison of nanopore sequencing workflow with and without Endonuclease I digest. EN: Endonuclease I digest.

Table 1: Nanopore sequencing results in comparison with aCGH.


20 Patients
102 Pooled polar bodies
WGA
PGT-A routine analysis (aCGH)
aCGH result (n=102)
1 Sample excluded (Pb61)
Quality check (n=101)
1 Sample excluded (Pb95)
100 aCGH results
WGA aliquot
Library preperation
Nanopore sequencing
Data analysis
Nanopore result (n=102)
Quality check (n=102)
1 Sample excluded (Pb48)
101 Nanopore results
Concordance rates (n=99)
Ploidy status
aCGH
Nanopore
Concordance
euploid euploid MATCH (n=29)
aneuploid aneuploid MATCH (n=67)
euploid aneuploid MISMATCH (n=0)
aneuploid euploid MISMATCH (n=3)
Concordance, Sensitivity, Specificity, PPV, NPV
Nanopore result
aneuploid
euploid
aCGH result
aneuploid
euploid
True Positive (n=67)
False Negative (n=3)
False Positive (n=0)
True Negative (n=29)
Concordance 97.0 %
Sensitivity 0.957
Specificity 1.0
PPV 1.0
NPV 0.906


b) Polar Body Biopsy
10 min / sample
PB1
PB2
c) gDNA extraction and WGA
2.5 h / sample
Polar body pooling
Repli-g Single Cell Kit
d) Library Preparation
1 h / sample
End preparation
Ligation of barcode and sequencing adapters
e) Nanopore Sequencing and Real-Time Analysis
1 h / sample, 40 € / sample
MinION Mk1C
Flow cell (R9.4.1)
Basecalling
f) Secondary Processing
5 min / sample
Data cleaning
Alignment
Copy-number analysis
Current (pA)
Time (ms)
Alignment
FastQ
g) Same-day result for aneuploidy screening
Copy number
MAPD
Noise
Chromosome
h) Selection for transfer
i) Transfer of embryo from euploid oocyte
a) Oocyte pick-up and ICSI


TP gains
FN gains
FP gains
TP losses
FN losses
FP losses
Occurrences
Chromosome
0
2
4
6
8
10
12
14
16
18
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X


a) euploid
b) aneuploid (+Chr. 22)
c) aneuploid (+Chr. 11, -Chr. 16)
d) aneuploid (+Chr. 10, +Chr. X)
e) aneuploid (-Chr. 2, +Chr. 9, -Chr. 15)
f) aneuploid (multiple)
Copy Number
MAPD
Noise


Sequencing Reads Generated
Read Number [x 1000]
0
50
100
150
200
250
Without EN
With EN
Noise Measured
Noise
0.0
0.1
0.2
0.3
0.4
0.5
Without EN
With EN
Full Karyotype Concordance
Concordant Samples
0
3
6
9
12
15
18
21
Without EN
With EN

Sample	Ploidy Status			Chromosome Aberrations		
Number	aCGH	Nanopore	Concordance	aCGH	Nanopore	Concordance
Pb1	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb2	aneuploid	aneuploid	CONCORDANT	+22	+22	CONCORDANT
Pb3	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb4	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb5	aneuploid	aneuploid	CONCORDANT	-1	-1	CONCORDANT
Pb6	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb7	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb8	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb9	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb10	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb11	aneuploid	aneuploid	CONCORDANT	-4	-4	CONCORDANT
Pb12	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb13	aneuploid	aneuploid	CONCORDANT	-15	-15	CONCORDANT
Pb14	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb15	aneuploid	aneuploid	CONCORDANT	-10, +14	-10, +14	CONCORDANT
Pb16	aneuploid	aneuploid	CONCORDANT	+10, +X	+10, +X	CONCORDANT
Pb17	aneuploid	aneuploid	CONCORDANT	-14, +20	-14, +20	CONCORDANT
Pb18	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb19	aneuploid	aneuploid	CONCORDANT	+16, -18, -20	+16, -18, -20	CONCORDANT
Pb20	aneuploid	aneuploid	CONCORDANT	-7, +16	multiple	DISCORDANT
Pb21	aneuploid	aneuploid	CONCORDANT	+19, -21, -22	-21	DISCORDANT
Pb22	aneuploid	aneuploid	CONCORDANT	+12, -13, -16	+12, -13, -16	CONCORDANT
Pb23	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb24	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb25	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb26	aneuploid	aneuploid	CONCORDANT	-16	-16	CONCORDANT
Pb27	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb28	aneuploid	aneuploid	CONCORDANT	-6, -12	-6, -12	CONCORDANT
Pb29	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb30	aneuploid	aneuploid	CONCORDANT	+11, +15, +22	+11, +15, +22	CONCORDANT
Pb31	aneuploid	aneuploid	CONCORDANT	-17	-17	CONCORDANT
Pb32	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb33	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb34	aneuploid	aneuploid	CONCORDANT	-13, -15, -21	-13, -15, -21	CONCORDANT
Pb35	aneuploid	aneuploid	CONCORDANT	-22	-22	CONCORDANT
Pb36	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb37	aneuploid	aneuploid	CONCORDANT	+16	+16	CONCORDANT
Pb38	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb39	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb40	aneuploid	aneuploid	CONCORDANT	+4	+4	CONCORDANT
Pb41	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb42	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb43	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb44	aneuploid	aneuploid	CONCORDANT	+15	+15	CONCORDANT
Pb45	aneuploid	aneuploid	CONCORDANT	+16, -19	+16, -19	CONCORDANT
Pb46	aneuploid	euploid	DISCORDANT	+22	-	DISCORDANT
Pb47	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb48	euploid	not evaluable	EXCLUDED	-		EXCLUDED
Pb49	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb50	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb51	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb52	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb53	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb54	aneuploid	aneuploid	CONCORDANT	-9, -15	-9, -15	CONCORDANT
Pb55	aneuploid	aneuploid	CONCORDANT	-17, -18	-17, -18	CONCORDANT
Pb56	aneuploid	aneuploid	CONCORDANT	-16	-16	CONCORDANT
Pb57	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb58	aneuploid	aneuploid	CONCORDANT	-13, -14, +17	multiple	DISCORDANT
Pb59	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb60	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb61	not evaluable	euploid	EXCLUDED		-	EXCLUDED
Pb62	aneuploid	euploid	DISCORDANT	+19	-	DISCORDANT
Pb63	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb64	aneuploid	aneuploid	CONCORDANT	+4	+4	CONCORDANT
Pb65	aneuploid	aneuploid	CONCORDANT	+16	+16	CONCORDANT
Pb66	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb67	aneuploid	aneuploid	CONCORDANT	+12, -15	+12, -15	CONCORDANT
Pb68	aneuploid	aneuploid	CONCORDANT	+2	+2	CONCORDANT
Pb69	aneuploid	aneuploid	CONCORDANT	+6, -18	+6, -18	CONCORDANT
Pb70	aneuploid	aneuploid	CONCORDANT	-16, -22	-16, -22	CONCORDANT
Pb71	aneuploid	aneuploid	CONCORDANT	+11, +16, -17	+11, +16, -17	CONCORDANT
Pb72	aneuploid	aneuploid	CONCORDANT	-19	-19	CONCORDANT
Pb73	aneuploid	aneuploid	CONCORDANT	+4, -20	+4, -20	CONCORDANT
Pb74	aneuploid	aneuploid	CONCORDANT	-16, +21	-16, +21	CONCORDANT
Pb75	aneuploid	aneuploid	CONCORDANT	+16, +22	+16, +22	CONCORDANT
Pb76	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb77	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb78	aneuploid	aneuploid	CONCORDANT	+17, -22	+17, -22	CONCORDANT
Pb79	aneuploid	aneuploid	CONCORDANT	+18	+18	CONCORDANT
Pb80	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb81	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb82	aneuploid	aneuploid	CONCORDANT	+9, -13	+9, -13	CONCORDANT
Pb83	aneuploid	aneuploid	CONCORDANT	+16, -19	+16, -19	CONCORDANT
Pb84	aneuploid	aneuploid	CONCORDANT	+1	+1	CONCORDANT
Pb85	aneuploid	euploid	DISCORDANT	-16	-	DISCORDANT
Pb86	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb87	aneuploid	aneuploid	CONCORDANT	+20	+20	CONCORDANT
Pb88	aneuploid	aneuploid	CONCORDANT	-17	-17	CONCORDANT
Pb89	aneuploid	aneuploid	CONCORDANT	+22	+22	CONCORDANT
Pb90	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb91	aneuploid	aneuploid	CONCORDANT	-2, +6	-2, +6	CONCORDANT
Pb92	aneuploid	aneuploid	CONCORDANT	multiple	multiple	CONCORDANT
Pb93	aneuploid	aneuploid	CONCORDANT	+1, -16, +19	+1, -16	DISCORDANT
Pb94	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb95	not evaluable	euploid	EXCLUDED		-	EXCLUDED
Pb96	aneuploid	aneuploid	CONCORDANT	+11,-16,+19	+11, -16	DISCORDANT
Pb97	aneuploid	aneuploid	CONCORDANT	+16	+16	CONCORDANT
Pb98	aneuploid	aneuploid	CONCORDANT	-4	-4	CONCORDANT
Pb99	aneuploid	aneuploid	CONCORDANT	+16	+16	CONCORDANT
Pb100	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb101	euploid	euploid	CONCORDANT	-	-	CONCORDANT
Pb102	euploid	euploid	CONCORDANT	-	-	CONCORDANT